NEW YORK, NY – September 30, 2013 – Ophthotech Corporation today announced the closing of its initial public offering of 8,740,000 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts, including 1,140,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.

Morgan Stanley and J.P. Morgan acted as joint book-running managers for the offering. Leerink Swann and Stifel acted as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 24, 2013. Copies of the final prospectus relating to this offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717; telephone: 866-803-9204.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye. The company’s most advanced product candidate is Fovista™ anti-PDGF therapy, which it is developing for use in combination with anti-VEGF drugs that represent the standard of care for the treatment of wet age-related macular degeneration.